Integrated genetic and pharmacologic interrogation of rare cancers

Nature Communications

Volumn 7, Issue , 2016, Pages

  Hong, Andrew L ^a,b,c   Tseng, Yuen Yi ^c   Cowley, Glenn S ^c,g   Jonas, Oliver ^d   Cheah, Jaime H ^d   Kynnap, Bryan D ^b   Doshi, Mihir B ^b,c   Oh, Coyin ^c   Meyer, Stephanie C ^a,b   Church, Alanna J ^a   Gill, Shubhroz ^c   Bielski, Craig M ^c,h   Keskula, Paula ^c   Imamovic, Alma ^b,c   Howell, Sara ^c   Kryukov, Gregory V ^c,e   Clemons, Paul A ^c   Tsherniak, Aviad ^c   Vazquez, Francisca ^c   Crompton, Brian D ^a,b   Shamji, Alykhan F ^c   Rodriguez Galindo, Carlos ^a,b,i   Janeway, Katherine A ^a,b   Roberts, Charles W M ^a,b,i   Stegmaier, Kimberly ^a,b,c   Van Hummelen, Paul ^b   Cima, Michael J ^d   Langer, Robert S ^d   Garraway, Levi A ^b,c,e,f   Schreiber, Stuart L ^c,f   Root, David E ^c   Hahn, William C ^b,c,e   Boehm, Jesse S ^c   more..

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g Discovery Sciences Janssen Pharmaceutical J and J   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL N [1,4,5,6 TETRAHYDRO 6,6 DIMETHYL 5 [(1 METHYL 4 PIPERIDINYL)CARBONYL]PYRROLO[3,4 C]PYRAZOL 3 YL]BUTANAMIDE; CASPASE 3; CYCLIN DEPENDENT KINASE 4; DOXORUBICIN; EXPORTIN 1; FLAVOPIRIDOL; PALBOCICLIB; SELINEXOR; ANTINEOPLASTIC AGENT; CDK4 PROTEIN, HUMAN; CELL RECEPTOR; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-330; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

CANCER; CELLS AND CELL COMPONENTS; DRUG; GENETIC ANALYSIS; GENOMICS; HISTOLOGY; INTEGRATED APPROACH; LESION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER RECURRENCE; CONTROLLED STUDY; CRISPR CAS SYSTEM; FUNCTIONAL GENOMICS; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POINT MUTATION; RARE DISEASE; RNA INTERFERENCE; RNA SEQUENCE; SARCOMA; SOMATIC MUTATION; UNDIFFERENTIATED SARCOMA; A-549 CELL LINE; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; DRUG SCREENING; EXOME; FEMALE; GENETICS; GENOMICS; METASTASIS; NUDE MOUSE; SEQUENCE ANALYSIS; TUMOR CELL LINE; TUMOR RECURRENCE;

A549 CELLS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; CYCLIN-DEPENDENT KINASE 4; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; EXOME; FEMALE; GENOMICS; HUMANS; HYDRAZINES; KARYOPHERINS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PIPERAZINES; PYRIDINES; RARE DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA INTERFERENCE; SARCOMA; SEQUENCE ANALYSIS, RNA; TRIAZOLES;

EID: 84975689909     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11987     Document Type: Article

References (39)

1. Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151-1161 (2013).
2. Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).
3. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
4. Connor, E. & Cure, P. "Creating hope" and other incentives for drug development for children. Sci. Transl. Med. 3, 66cm1 (2011).
5. Yuan, H. et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N. Engl. J. Med. 367, 1220-1227 (2012).
6. Ince, T. A. et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat. Commun. 6, 7419 (2015).
7. Oie, H. K., Russell, E. K., Carney, D. N. & Gazdar, A. F. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J. Cell. Biochem. Suppl. 24, 24-31 (1996).
8. Van Allen, E. M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20, 682-688 (2014).
9. Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale smallmolecule sensitivity dataset. Cancer Discov. 5, 1210-1223 (2015).
10. Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109-116 (2016).
11. Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).
12. Kaelin, Jr. W. G. Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science 337, 421-422 (2012).
13. Buehler, E., Chen, Y. C. & Martin, S. C911: a bench-level control for sequence specific siRNA off-target effects. PLoS ONE 7, e51942 (2012).
14. Luo, B. et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl Acad. Sci. USA 105, 20380-20385 (2008).
15. Rao, M. et al. Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells. Clin. Cancer Res. 22, 1197-1210 (2015).
16. Cheung, H. W. et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl Acad. Sci. USA 108, 12372-12377 (2011).
17. Kennedy, A. L. et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget 6, 30178-30193 (2015).
18. Tsikitis, M., Zhang, Z., Edelman, W., Zagzag, D. & Kalpana, G. V. Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc. Natl Acad. Sci. USA 102, 12129-12134 (2005).
19. Gravina, G. L. et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol. 7, 85 (2014).
20. Dayal, S. et al. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J. Biol. Chem. 284, 5030-5041 (2009).
21. Jonas, O. et al. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci. Transl. Med. 7, 284ra57 (2015).
22. Pappo, A. S. et al. Rare tumors in children: progress through collaboration. J. Clin. Oncol. 33, 3047-3054 (2015).
23. Gatta, G. et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer 47, 2493-2511 (2011).
24. Boyd, N., Dancey, J. E., Gilks, C. B. & Huntsman, D. G. Rare cancers: a sea of opportunity. Lancet Oncol. 17, e52-e61 (2016).
25. Shaw, A. T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014).
26. Wong, D. W. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115, 1723-1733 (2009).
27. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
28. Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer. Discov. 6, 353-367 (2015).
29. Attiyeh, E. F. et al. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the pediatric preclinical testing program. Pediatr. Blood Cancer. 63, 276-286 (2016).
30. Suggitt, M. & Bibby, M. C. 50 Years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 11, 971-981 (2005).
31. Hait, W. N. Anticancer drug development: the grand challenges. Nat. Rev. Drug Discov. 9, 253-254 (2010).
32. Begley, C. G. & Ellis, L. M. Drug development: raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
33. Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer. 15, 311-316 (2015).
34. Gifford, C. A. et al. Transcriptional and epigenetic dynamics during specification of human embryonic stem cells. Cell 153, 1149-1163 (2013).
35. Torres-Garcia, W. et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30, 2224-2226 (2014).
36. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
37. Iyer, M. K., Chinnaiyan, A. M. & Maher, C. A. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 27, 2903-2904 (2011).
38. Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262-1267 (2014).
39. Shalem, O., Sanjana, N. E. & Zhang, F. High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16, 299-311 (2015).